
CLOV does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for CLOV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for CLOV and 80,000+ other tickers.
See exactly how CLOV's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CLOV and 80,000+ other tickers.
Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) health plans for individuals eligible for Medicare. In addition to its insurance operations, Clover Health also engages in non-insurance-related business ventures. The company was established in 2014 and its main office is located in Franklin, Tennessee.

Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report) insider Karen Soares sold 14,673 shares of Clover Health Investments stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $4.68, for a total transaction of $68,669.64. Following the sale, the insider directly owned 1,592,698 shares of the company's

Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report) CEO Andrew Toy sold 62,176 shares of the firm's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.68, for a total value of $290,983.68. Following the sale, the chief executive officer owned 9,078,334 shares in the company,

Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report) CEO Conrad Wai sold 23,627 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $4.68, for a total value of $110,574.36. Following the completion of the transaction, the chief executive officer owned

WILMINGTON, Del., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health” or “Clover”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it earned top distinctions across New Jersey, Georgia, and South Carolina in U.S. News & World Report's 2027 Best Insurance Companies for Medicare Advantage (“MA”) ratings.

WILMINGTON, Del., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare & Medicaid Services (“CMS”) has awarded its PPO Medicare Advantage (“MA”) plans a rating of 5 Stars and its HMO MA plan a rating of 4.5 Stars for 2027, which will affect payment year 2028.